Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Feb;84(4):579–585. doi: 10.1054/bjoc.2000.1600

Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines

J-L Fischel 1, P Rostagno 1, P Formento 1, A Dubreuil 1, M-C Etienne 1, G Milano 1
PMCID: PMC2363774  PMID: 11207057

Abstract

A marked antitumour efficacy is currently obtained by oxaliplatin (LOHP)–fluorouracil (FU)–folinic acid (FA) combination and by CPT11–FU–FA combination. Logically, the triple association LOHP, CPT11 and FUFA will be soon tested in cancer patients. The aim of the present study was to compare two schedules combining SN38 (the active metabolite of CPT11, irinotecan) with FU–FA and LOHP. The two schedules differed by the SN38 position. The relative contribution of each drug in the resulting global cytotoxicity was evaluated. Two human colon cancer cell lines were used (WIDR and SW620 both p53 mutated). LOHP plus FA were applied for 2 h, just before a 48 h FU exposure. The SN38 sequence was applied for 24 h, starting either 48 h before LOHP-FA (schedule A), or just after LOHP-FA exposure (schedule B). Cytotoxicity was assessed by the 3-(4,5-demethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT) test and drug interactions were analysed according to the Chou and Talalay method, based on the computation of a combination index (CI). The SN38 position significantly induces a shift from additivity-antagonism when SN38 was applied after LOHP, towards additivity-synergism when SN38 was applied first (P = 0.03). The relative contribution (RC) of each drug in the overall cytotoxicity of the triple combination was defined as the drug concentration giving 50% cell lethality (IC 50) of the double association without that drug divided by the IC 50 of the triple association. Whatever the SN38 position, the larger contribution was made by LOHP (median RC = 2.4) and the smaller by SN38 (median RC = 1.1). In addition, the contribution of FUFA was improved when SN38 was applied first (median RC = 2.2) as compared to the opposite schedule (median RC = 1.2). Results were in agreement between the two explored cell lines. The present data should be taken into account when establishing the rationale of future trials combining CPT11, LOHP and FU–FA. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: irinotecan, fluorouracil, oxaliplatin, colon cancer cell lines, drug combination

Full Text

The Full Text of this article is available as a PDF (202.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baisch H., Göhde W., Linden W. A. Analysis of PCP-data to determine the fraction of cells in the various phases of cell cycle. Radiat Environ Biophys. 1975 Jun 13;12(1):31–39. doi: 10.1007/BF02339807. [DOI] [PubMed] [Google Scholar]
  2. Carmichael J., DeGraff W. G., Gazdar A. F., Minna J. D., Mitchell J. B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 1987 Feb 15;47(4):936–942. [PubMed] [Google Scholar]
  3. Chou T. C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27–55. doi: 10.1016/0065-2571(84)90007-4. [DOI] [PubMed] [Google Scholar]
  4. Cunningham D., Pyrhönen S., James R. D., Punt C. J., Hickish T. F., Heikkila R., Johannesen T. B., Starkhammar H., Topham C. A., Awad L. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998 Oct 31;352(9138):1413–1418. doi: 10.1016/S0140-6736(98)02309-5. [DOI] [PubMed] [Google Scholar]
  5. Douillard J. Y., Cunningham D., Roth A. D., Navarro M., James R. D., Karasek P., Jandik P., Iveson T., Carmichael J., Alakl M. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000 Mar 25;355(9209):1041–1047. doi: 10.1016/s0140-6736(00)02034-1. [DOI] [PubMed] [Google Scholar]
  6. Fischel J. L., Etienne M. C., Formento P., Milano G. Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: preclinical data. Clin Cancer Res. 1998 Oct;4(10):2529–2535. [PubMed] [Google Scholar]
  7. Goldwasser F., Shimizu T., Jackman J., Hoki Y., O'Connor P. M., Kohn K. W., Pommier Y. Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res. 1996 Oct 1;56(19):4430–4437. [PubMed] [Google Scholar]
  8. Guichard S., Cussac D., Hennebelle I., Bugat R., Canal P. Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo. Int J Cancer. 1997 Nov 27;73(5):729–734. doi: 10.1002/(sici)1097-0215(19971127)73:5<729::aid-ijc20>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  9. Houghton J. A., Schmidt C., Houghton P. J. The effect of derivatives of folic acid on the fluorodeoxyuridylate-thymidylate synthetase covalent complex in human colon xenografts. Eur J Cancer Clin Oncol. 1982 Apr;18(4):347–354. doi: 10.1016/0277-5379(82)90005-0. [DOI] [PubMed] [Google Scholar]
  10. Kones R. Folic acid, 1991: an update, with new recommended daily allowances. South Med J. 1990 Dec;83(12):1454–1458. [PubMed] [Google Scholar]
  11. Kressner U., Inganäs M., Byding S., Blikstad I., Påhlman L., Glimelius B., Lindmark G. Prognostic value of p53 genetic changes in colorectal cancer. J Clin Oncol. 1999 Feb;17(2):593–599. doi: 10.1200/JCO.1999.17.2.593. [DOI] [PubMed] [Google Scholar]
  12. Milano G., Etienne M. C. Potential importance of dihydropyrimidine dehydrogenase (DPD) in cancer chemotherapy. Pharmacogenetics. 1994 Dec;4(6):301–306. doi: 10.1097/00008571-199412000-00002. [DOI] [PubMed] [Google Scholar]
  13. O'Reilly S., Rowinsky E. K. The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue: 1996. Crit Rev Oncol Hematol. 1996 Sep;24(1):47–70. doi: 10.1016/1040-8428(96)00211-9. [DOI] [PubMed] [Google Scholar]
  14. Pavillard V., Formento P., Rostagno P., Formento J. L., Fischel J. L., Francoual M., Etienne M. C., Milano G. Combination of irinotecan (CPT11) and 5-fluorouracil with an analysis of cellular determinants of drug activity. Biochem Pharmacol. 1998 Nov 15;56(10):1315–1322. doi: 10.1016/s0006-2952(98)00205-6. [DOI] [PubMed] [Google Scholar]
  15. Ratain M. J. Drug combinations: dangerous liaisons or great expectations? Ann Oncol. 1999 Apr;10(4):375–376. doi: 10.1023/a:1008311912161. [DOI] [PubMed] [Google Scholar]
  16. Raymond E., Buquet-Fagot C., Djelloul S., Mester J., Cvitkovic E., Allain P., Louvet C., Gespach C. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs. 1997 Oct;8(9):876–885. doi: 10.1097/00001813-199710000-00009. [DOI] [PubMed] [Google Scholar]
  17. Raymond E., Chaney S. G., Taamma A., Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998 Oct;9(10):1053–1071. doi: 10.1023/a:1008213732429. [DOI] [PubMed] [Google Scholar]
  18. Rougier P., Van Cutsem E., Bajetta E., Niederle N., Possinger K., Labianca R., Navarro M., Morant R., Bleiberg H., Wils J. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 1998 Oct 31;352(9138):1407–1412. doi: 10.1016/S0140-6736(98)03085-2. [DOI] [PubMed] [Google Scholar]
  19. Saltz L. B., Cox J. V., Blanke C., Rosen L. S., Fehrenbacher L., Moore M. J., Maroun J. A., Ackland S. P., Locker P. K., Pirotta N. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000 Sep 28;343(13):905–914. doi: 10.1056/NEJM200009283431302. [DOI] [PubMed] [Google Scholar]
  20. Scanlon K. J., Newman E. M., Lu Y., Priest D. G. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci U S A. 1986 Dec;83(23):8923–8925. doi: 10.1073/pnas.83.23.8923. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Scheithauer W., Kornek G. V., Raderer M., Valencak J., Weinländer G., Hejna M., Haider K., Kwasny W., Depisch D. Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. J Clin Oncol. 1999 Mar;17(3):902–906. doi: 10.1200/JCO.1999.17.3.902. [DOI] [PubMed] [Google Scholar]
  22. Shirasaka T., Shimamoto Y., Ohshimo H., Saito H., Fukushima M. Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother Pharmacol. 1993;32(3):167–172. doi: 10.1007/BF00685830. [DOI] [PubMed] [Google Scholar]
  23. Valencak J., Raderer M., Kornek G. V., Henja M. H., Scheithauer W. Irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin. J Natl Cancer Inst. 1998 Jan 21;90(2):160–160. doi: 10.1093/jnci/90.2.160. [DOI] [PubMed] [Google Scholar]
  24. Vindeløv L. L., Christensen I. J., Nissen N. I. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry. 1983 Mar;3(5):323–327. doi: 10.1002/cyto.990030503. [DOI] [PubMed] [Google Scholar]
  25. Wasserman E., Cuvier C., Lokiec F., Goldwasser F., Kalla S., Méry-Mignard D., Ouldkaci M., Besmaine A., Dupont-André G., Mahjoubi M. Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics. J Clin Oncol. 1999 Jun;17(6):1751–1759. doi: 10.1200/JCO.1999.17.6.1751. [DOI] [PubMed] [Google Scholar]
  26. Zeghari-Squalli N., Raymond E., Cvitkovic E., Goldwasser F. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. Clin Cancer Res. 1999 May;5(5):1189–1196. [PubMed] [Google Scholar]
  27. de Gramont A., Figer A., Seymour M., Homerin M., Hmissi A., Cassidy J., Boni C., Cortes-Funes H., Cervantes A., Freyer G. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000 Aug;18(16):2938–2947. doi: 10.1200/JCO.2000.18.16.2938. [DOI] [PubMed] [Google Scholar]
  28. de Gramont A., Vignoud J., Tournigand C., Louvet C., André T., Varette C., Raymond E., Moreau S., Le Bail N., Krulik M. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer. 1997 Feb;33(2):214–219. doi: 10.1016/s0959-8049(96)00370-x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES